Linezolid-related Optic Nerve Disorders: Insight From a Pharmacovigilance Analysis of the US FDA Adverse Event Reporting System.

ABSTRACT:

Background

Linezolid is a crucial oxazolidinone used to treat multidrug-resistant gram-positive infections; however, it is associated with optic neuropathy and other adverse events. Data regarding the usage and toxicity features of linezolid and those of tedizolid, a related agent with a potentially improved safety profile, are limited. Therefore, this study aimed to investigate the signals and characterize the clinical features of optic nerve disorders related to oxazolidinones using the Food and Drug Administration Adverse Event Reporting System (FAERS) database.

Methods

This retrospective pharmacovigilance study examined FAERS data from July 2014 to April 2024. Disproportionality analyses (reporting odds ratio [ROR] and information component [IC]) were conducted to detect

SUBMITTER: Nakano Y 

PROVIDER: S-EPMC12445842 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature